Handelen Novartis Adr Repsg 1 - USD - NVS CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.30 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
| Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Novartis AG ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 88.17 |
| Open* | 86.28 |
| 1-Jaarlijkse Verandering* | -2.11% |
| Dagelijks bereik* | 85.6 - 86.28 |
| 52 wekelijks bereik | 74.09-94.26 |
| Weekgemiddelde volume (10 dagen) | 2.22M |
| Gemiddeld volume (3 maanden) | 40.93M |
| Marktkapitalisatie | 212.32B |
| P/E Ratio | 27.92 |
| Uitstaande Aandelen | 2.12B |
| Omzet | 51.74B |
| EPS | 3.16 |
| Dividend (opbrengst %) | 3.76884 |
| Beta | 0.52 |
| Volgende inkomsten datum | Apr 25, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Feb 2, 2023 | 86.07 | -0.40 | -0.46% | 86.47 | 86.53 | 85.42 |
| Feb 1, 2023 | 88.17 | 0.10 | 0.11% | 88.07 | 88.52 | 85.97 |
| Jan 31, 2023 | 90.53 | 1.00 | 1.12% | 89.53 | 90.59 | 89.10 |
| Jan 30, 2023 | 89.55 | -0.48 | -0.53% | 90.03 | 90.36 | 89.36 |
| Jan 27, 2023 | 89.43 | 0.13 | 0.15% | 89.30 | 89.95 | 89.20 |
| Jan 26, 2023 | 89.63 | -1.31 | -1.44% | 90.94 | 91.03 | 89.29 |
| Jan 25, 2023 | 92.72 | 0.62 | 0.67% | 92.10 | 92.83 | 92.09 |
| Jan 24, 2023 | 91.80 | 0.54 | 0.59% | 91.26 | 92.10 | 90.32 |
| Jan 23, 2023 | 91.95 | 0.20 | 0.22% | 91.75 | 92.47 | 91.71 |
| Jan 20, 2023 | 92.02 | 0.06 | 0.07% | 91.96 | 92.02 | 91.18 |
| Jan 19, 2023 | 92.19 | 0.17 | 0.18% | 92.02 | 92.32 | 91.83 |
| Jan 18, 2023 | 92.05 | -1.15 | -1.23% | 93.20 | 93.21 | 91.97 |
| Jan 17, 2023 | 92.32 | -0.85 | -0.91% | 93.17 | 93.17 | 92.18 |
| Jan 13, 2023 | 91.02 | 0.38 | 0.42% | 90.64 | 91.23 | 90.37 |
| Jan 12, 2023 | 90.48 | 0.49 | 0.54% | 89.99 | 90.83 | 89.59 |
| Jan 11, 2023 | 90.23 | -0.62 | -0.68% | 90.85 | 90.93 | 90.01 |
| Jan 10, 2023 | 90.20 | 0.02 | 0.02% | 90.18 | 90.79 | 89.73 |
| Jan 9, 2023 | 89.66 | -3.26 | -3.51% | 92.92 | 93.20 | 89.32 |
| Jan 6, 2023 | 92.20 | 1.13 | 1.24% | 91.07 | 92.39 | 90.50 |
| Jan 5, 2023 | 90.75 | -0.25 | -0.27% | 91.00 | 91.20 | 90.41 |
Novartis Adr Repsg 1 - USD Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 49386 | 43361 | 46017 | 48624 | 49898 | 52877 |
| Inkomsten | 49386 | 43361 | 46017 | 48624 | 49898 | 52877 |
| Kosten van opbrengsten, totaal | 17338 | 13416 | 13555 | 13930 | 14400 | 15435 |
| Brutowinst | 32048 | 29945 | 32462 | 34694 | 35498 | 37442 |
| Totale bedrijfskosten | 41111 | 34658 | 31824 | 39538 | 39746 | 41188 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 14111 | 12468 | 13690 | 14319 | 14093 | 14815 |
| Onderzoek & Ontwikkeling | 8402 | 7808 | 8154 | 8386 | 8484 | 9041 |
| Depreciation / Amortization | 43 | 187 | 179 | 50 | 64 | 109 |
| Ongebruikelijke uitgaven (inkomsten) | 911 | 395 | -4309 | 2284 | 2503 | 1173 |
| Other Operating Expenses, Total | 306 | 384 | 549 | 607 | 538 | 653 |
| Bedrijfsresultaat | 8275 | 8703 | 14193 | 9086 | 10152 | 11689 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -440 | 418 | -5 | -36 | -146 | 14628 |
| Overige, Netto | -18 | -19 | -93 | -110 | -128 | -180 |
| Netto inkomen voor belastingen | 7817 | 9102 | 14095 | 8940 | 9878 | 26137 |
| Netto inkomen na belastingen | 6698 | 7499 | 12800 | 7147 | 8071 | 24018 |
| Minderheidsbelang | 14 | 0 | -3 | -5 | 1 | 3 |
| Netto inkomen voor extra. Posten | 6712 | 7499 | 12797 | 7142 | 8072 | 24021 |
| Netto inkomen | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 6712 | 7499 | 12797 | 7142 | 8072 | 24021 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Verwateringsaanpassing | 0 | |||||
| Verwaterd Netto Inkomen | 6712 | 7703 | 12611 | 11732 | 8072 | 24021 |
| Verwaterd Gewogen Gemiddelde Aandelen | 2400 | 2371 | 2344 | 2319 | 2296 | 2260 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 2.79667 | 3.1628 | 5.45947 | 3.07978 | 3.51568 | 10.6288 |
| Dividends per Share - Common Stock Primary Issue | 2.71795 | 2.71776 | 2.93645 | 2.83413 | 3.08737 | 3.19907 |
| Verwaterde Genormaliseerde Winst per Aandeel | 3.12191 | 3.30006 | 3.79006 | 3.86715 | 4.40641 | 11.1183 |
| Totale buitengewone posten | 204 | -186 | 4590 | |||
| Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | 6 | -38 | -336 | -38 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 12694 | 13294 | 13367 | 13522 | 12814 |
| Inkomsten | 12694 | 13294 | 13367 | 13522 | 12814 |
| Kosten van opbrengsten, totaal | 3833 | 3754 | 3848 | 4000 | 3755 |
| Brutowinst | 8861 | 9540 | 9519 | 9522 | 9059 |
| Totale bedrijfskosten | 10279 | 9815 | 10134 | 10960 | 9962 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3520 | 3710 | 3601 | 3984 | 3498 |
| Onderzoek & Ontwikkeling | 2127 | 2284 | 2261 | 2369 | 2256 |
| Depreciation / Amortization | 27 | 27 | 25 | 30 | 35 |
| Rentekosten (inkomsten) - Operationeel nettobedrijfsresultaat | -101 | 60 | -9 | 12 | 102 |
| Ongebruikelijke uitgaven (inkomsten) | 690 | -136 | 312 | 307 | 193 |
| Other Operating Expenses, Total | 183 | 116 | 96 | 258 | 123 |
| Bedrijfsresultaat | 2415 | 3479 | 3233 | 2562 | 2852 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 54 | 38 | 21 | 14415 | -203 |
| Overige, Netto | -19 | -11 | -24 | -26 | 20 |
| Netto inkomen voor belastingen | 2450 | 3506 | 3230 | 16951 | 2669 |
| Netto inkomen na belastingen | 2059 | 2895 | 2758 | 16306 | 2219 |
| Minderheidsbelang | 0 | 1 | 0 | 2 | 3 |
| Netto inkomen voor extra. Posten | 2059 | 2896 | 2758 | 16308 | 2222 |
| Netto inkomen | 2059 | 2896 | 2758 | 16308 | 2222 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 2059 | 2896 | 2758 | 16308 | 2222 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 2059 | 2896 | 2758 | 16308 | 2222 |
| Verwaterd Netto Inkomen | 2059 | 2896 | 2758 | 16308 | 2222 |
| Verwaterd Gewogen Gemiddelde Aandelen | 2265 | 2243 | 2254 | 2257 | 2237 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.90905 | 1.29113 | 1.2236 | 7.22552 | 0.99329 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 3.19907 | 0 |
| Verwaterde Genormaliseerde Winst per Aandeel | 1.16507 | 1.24106 | 1.3418 | 7.35637 | 1.06502 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 24931 | 28208 | 35563 | 29504 | 29673 | 45718 |
| Geldmiddelen en kortetermijnbeleggingen | 7546 | 9347 | 15718 | 11234 | 11293 | 28113 |
| Cash | 1912 | 2970 | 3121 | 3247 | 3750 | 3396 |
| Geldmiddelen & Equivalenten | 5095 | 5890 | 10150 | 7865 | 5908 | 9011 |
| Korte Termijn Investeringen | 539 | 487 | 2447 | 122 | 1635 | 15706 |
| Totale Vorderingen, Netto | 10208 | 11101 | 11036 | 10337 | 10036 | 9621 |
| Accounts Receivable - Trade, Net | 8203 | 8601 | 8739 | 8301 | 8217 | 8005 |
| Total Inventory | 6255 | 6867 | 6956 | 5982 | 7131 | 6666 |
| Prepaid Expenses | 692 | 756 | 812 | 898 | 943 | 1102 |
| Other Current Assets, Total | 230 | 137 | 1041 | 1053 | 270 | 216 |
| Total Assets | 130124 | 133079 | 145563 | 118370 | 127778 | 131795 |
| Property/Plant/Equipment, Total - Net | 15641 | 16464 | 15696 | 13746 | 13939 | 13106 |
| Property/Plant/Equipment, Total - Gross | 31296 | 34010 | 34028 | 28676 | 29894 | 28708 |
| Accumulated Depreciation, Total | -15655 | -17546 | -18332 | -14930 | -15955 | -15602 |
| Goodwill, Net | 30980 | 31750 | 35294 | 26524 | 29999 | 29595 |
| Intangibles, Net | 31340 | 29997 | 38719 | 28787 | 36809 | 34182 |
| Long Term Investments | 15400 | 16645 | 9789 | 10538 | 11611 | 2268 |
| Note Receivable - Long Term | 1100 | 968 | 908 | 624 | 922 | 973 |
| Other Long Term Assets, Total | 10732 | 9047 | 9594 | 8647 | 4825 | 5953 |
| Total Current Liabilities | 22209 | 23403 | 29607 | 28264 | 33059 | 30208 |
| Accounts Payable | 4873 | 5169 | 5556 | 5424 | 5403 | 5553 |
| Accrued Expenses | 4169 | 4811 | 5105 | 5058 | 5336 | 5100 |
| Notes Payable/Short Term Debt | 5611 | 4842 | 6430 | 4844 | 7319 | 3606 |
| Current Port. of LT Debt/Capital Leases | 178 | 359 | 3190 | 2248 | 2558 | 2896 |
| Other Current Liabilities, Total | 7378 | 8222 | 9326 | 10690 | 12443 | 13053 |
| Total Liabilities | 55292 | 58911 | 66949 | 62896 | 71180 | 64140 |
| Total Long Term Debt | 17897 | 23224 | 22470 | 22056 | 27978 | 24523 |
| Long Term Debt | 17897 | 23224 | 22470 | 20353 | 26259 | 22902 |
| Deferred Income Tax | 6657 | 5168 | 7475 | 5867 | 3141 | 3070 |
| Minority Interest | 59 | 59 | 78 | 77 | 68 | 167 |
| Other Liabilities, Total | 8470 | 7057 | 7319 | 6632 | 6934 | 6172 |
| Total Equity | 74832 | 74168 | 78614 | 55474 | 56598 | 67655 |
| Common Stock | 972 | 969 | 944 | 936 | 913 | 901 |
| Retained Earnings (Accumulated Deficit) | 81148 | 77639 | 82191 | 59274 | 57157 | 70989 |
| Treasury Stock - Common | -76 | -100 | -69 | -80 | -53 | -48 |
| Unrealized Gain (Loss) | 348 | 386 | 206 | |||
| Other Equity, Total | -7560 | -4726 | -4658 | -4656 | -1419 | -4187 |
| Total Liabilities & Shareholders’ Equity | 130124 | 133079 | 145563 | 118370 | 127778 | 131795 |
| Total Common Shares Outstanding | 2374.06 | 2317.46 | 2311.17 | 2265.01 | 2256.82 | 2234.94 |
| Capital Lease Obligations | 1703 | 1719 | 1621 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 22198 | 23808 | 26253 | 45718 | 37236 |
| Geldmiddelen en kortetermijnbeleggingen | 4077 | 5356 | 8162 | 28329 | 18814 |
| Geldmiddelen & Equivalenten | 3801 | 5117 | 7211 | 12407 | 13852 |
| Korte Termijn Investeringen | 276 | 239 | 951 | 15922 | 4962 |
| Totale Vorderingen, Netto | 8481 | 8654 | 8632 | 8283 | 8678 |
| Accounts Receivable - Trade, Net | 8265 | 8400 | 8377 | 8005 | 8409 |
| Total Inventory | 6997 | 7111 | 6885 | 6666 | 6997 |
| Other Current Assets, Total | 2643 | 2687 | 2574 | 2440 | 2747 |
| Total Assets | 121752 | 124015 | 121209 | 131795 | 125218 |
| Property/Plant/Equipment, Total - Net | 13204 | 13344 | 13157 | 13106 | 12861 |
| Goodwill, Net | 29590 | 29766 | 29572 | 29595 | 29636 |
| Intangibles, Net | 35377 | 34818 | 33951 | 34182 | 34853 |
| Long Term Investments | 11628 | 12014 | 12347 | 3241 | 2906 |
| Other Long Term Assets, Total | 9755 | 10265 | 5929 | 5953 | 7726 |
| Total Current Liabilities | 30160 | 29633 | 29880 | 30208 | 29807 |
| Accounts Payable | 5040 | 4811 | 4665 | 5553 | 5083 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 10400 | 9278 | 9528 | 6502 | 6902 |
| Other Current Liabilities, Total | 14720 | 15544 | 15687 | 18153 | 17822 |
| Total Liabilities | 71229 | 69973 | 64438 | 64140 | 63678 |
| Total Long Term Debt | 27399 | 26491 | 24715 | 24523 | 24373 |
| Long Term Debt | 25747 | 24828 | 23101 | 22902 | 22796 |
| Capital Lease Obligations | 1652 | 1663 | 1614 | 1621 | 1577 |
| Deferred Income Tax | 7393 | 7472 | 3349 | 3070 | 3384 |
| Minority Interest | 66 | 86 | 166 | 167 | 164 |
| Other Liabilities, Total | 6211 | 6291 | 6328 | 6172 | 5950 |
| Total Equity | 50523 | 54042 | 56771 | 67655 | 61540 |
| Common Stock | 913 | 913 | 901 | 901 | 901 |
| Retained Earnings (Accumulated Deficit) | 49670 | 53194 | 55917 | 66802 | 60699 |
| Treasury Stock - Common | -60 | -65 | -47 | -48 | -60 |
| Total Liabilities & Shareholders’ Equity | 121752 | 124015 | 121209 | 131795 | 125218 |
| Total Common Shares Outstanding | 2245.09 | 2236.74 | 2237.09 | 2234.94 | 2212.58 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | 6698 | 7499 | 12800 | 7147 | 8071 | 24018 |
| Geldmiddelen uit Operationele Activiteiten | 11475 | 12621 | 14272 | 13625 | 13650 | 15071 |
| Geldmiddelen uit Operationele Activiteiten | 1591 | 1460 | 1783 | 1852 | 2088 | 1807 |
| Amortization | 4452 | 3276 | 3428 | 3974 | 4376 | 4306 |
| Niet-Geldelijke Posten | 2239 | 1983 | -2315 | 3369 | 3842 | -11714 |
| Cash Taxes Paid | 2111 | 1487 | 1506 | 1876 | 1833 | 2342 |
| Contant Betaalde Rente | 723 | 697 | 816 | 793 | 703 | 664 |
| Veranderingen in het Operationeel Kapitaal | -3505 | -1597 | -1424 | -2717 | -4727 | -3346 |
| Geldmiddelen uit Investeringsactiviteiten | -3441 | -3119 | -5591 | -2226 | -13182 | 4208 |
| Kapitaaluitgaven | -2879 | -2294 | -2648 | -2257 | -2585 | -2971 |
| Overige Cash Flow investeringsposten, Totaal | -562 | -825 | -2943 | 31 | -10597 | 7179 |
| Geldmiddelen uit Financieringsactiviteiten | -5314 | -7733 | -4244 | -13627 | -2208 | -16264 |
| Financiering van Cash Flow Posten | 1 | -101 | -119 | 3307 | -199 | 94 |
| Total Cash Dividends Paid | -6475 | -6495 | -6966 | -6645 | -6987 | -7368 |
| Uitgifte (Aflossing) van aandelen, netto | -895 | -5238 | -1336 | -5332 | -2094 | -3004 |
| Uitgifte (Aflossing) van Schulden, Netto | 2055 | 4101 | 4177 | -4957 | 7072 | -5986 |
| Wisselkoerseffecten | -387 | 84 | -26 | 69 | 286 | -266 |
| Nettowijziging in Geldmiddelen | 2333 | 1853 | 4411 | -2159 | -1454 | 2749 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2059 | 4954 | 7712 | 24018 | 2219 |
| Cash From Operating Activities | 2130 | 6262 | 11187 | 15071 | 1649 |
| Cash From Operating Activities | 514 | 893 | 1287 | 1807 | 392 |
| Amortization | 1183 | 2248 | 3307 | 4306 | 1013 |
| Non-Cash Items | 386 | 803 | 1732 | -11714 | 918 |
| Cash Taxes Paid | 735 | 1144 | 1459 | 2342 | 633 |
| Cash Interest Paid | 112 | 301 | 458 | 664 | 110 |
| Changes in Working Capital | -2012 | -2636 | -2851 | -3346 | -2893 |
| Cash From Investing Activities | 780 | 877 | -355 | 4208 | 9365 |
| Capital Expenditures | -858 | -1455 | -1994 | -2971 | -859 |
| Other Investing Cash Flow Items, Total | 1638 | 2332 | 1639 | 7179 | 10224 |
| Cash From Financing Activities | -8540 | -11479 | -13013 | -16264 | -9528 |
| Financing Cash Flow Items | -35 | 77 | 87 | 94 | 22 |
| Total Cash Dividends Paid | -7368 | -7368 | -7368 | -7368 | -7506 |
| Issuance (Retirement) of Stock, Net | -1892 | -2572 | -2856 | -3004 | -2448 |
| Issuance (Retirement) of Debt, Net | 755 | -1616 | -2876 | -5986 | 404 |
| Foreign Exchange Effects | -227 | -201 | -266 | -266 | -41 |
| Net Change in Cash | -5857 | -4541 | -2447 | 2749 | 1445 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| JPMorgan Private Bank (United States) | Bank and Trust | 10.6401 | 225529101 | 225420578 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 0.993 | 21048657 | -1504112 | 2022-09-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 0.8234 | 17453150 | -150930 | 2022-09-30 | LOW |
| Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 0.7044 | 14929752 | -555468 | 2022-09-30 | LOW |
| Franklin Mutual Advisers, LLC | Investment Advisor/Hedge Fund | 0.3354 | 7110172 | -288168 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.3068 | 6503191 | 465677 | 2022-09-30 | LOW |
| Managed Account Advisors LLC | Investment Advisor | 0.2611 | 5534681 | 606410 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 0.24 | 5087602 | 482080 | 2022-09-30 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 0.2136 | 4527461 | 83210 | 2022-09-30 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.1674 | 3547598 | -646574 | 2022-09-30 | HIGH |
| Schafer Cullen Capital Management, Inc. | Investment Advisor/Hedge Fund | 0.1636 | 3467273 | 103941 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.1583 | 3355379 | 61238 | 2022-09-30 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.1575 | 3339270 | 149986 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1501 | 3181870 | -601500 | 2022-09-30 | HIGH |
| Parametric Portfolio Associates LLC | Investment Advisor | 0.1273 | 2697639 | -319733 | 2022-09-30 | LOW |
| Northern Trust Global Investments | Investment Advisor | 0.1168 | 2475187 | -138624 | 2022-09-30 | LOW |
| Principal Global Investors (Equity) | Investment Advisor | 0.116 | 2458231 | 189855 | 2022-09-30 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1105 | 2341152 | -263161 | 2022-09-30 | LOW |
| Wells Fargo Advisors | Research Firm | 0.0936 | 1984665 | -300512 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0909 | 1927277 | -42628 | 2022-09-30 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group +485000+
Handelaren
65000+
Actieve klanten per maand
$48000000+
Maandelijks beleggingsvolume
$28000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Handelscommissie
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Hefboom
20:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Novartis ADR Company profile
Over Novartis Adr Repsg 1 - USD
Novartis AG is een in Zwitserland gevestigd farmaceutisch bedrijf. Het bedrijf ontwikkelt, produceert en verkoopt merkgeneesmiddelen en generieke geneesmiddelen op recept, actieve farmaceutische ingrediënten (API's), biosimilars en oogheelkundige producten. De onderneming maakt gebruik van wetenschappelijke en digitale technologieën voor behandelingen op het gebied van immunologie, dermatologie, kanker, oogheelkunde, neurowetenschappen, ademhalingsstelsel, cardiovasculaire aandoeningen, nieraandoeningen en metabolisme. De bedrijfsactiviteiten van de onderneming zijn onderverdeeld in twee segmenten: Innovatieve Geneesmiddelen, waaronder innovatieve, gepatenteerde receptgeneesmiddelen voor bloeddruk, kanker en andere aandoeningen, en Sandoz, waaronder generieke farmaceutische producten en biosimilars.
| Industry: | Pharmaceuticals (NEC) |
Lichtstrasse 35
BASEL
BASEL-STADT 4056
CH
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen